What is it about?
Chronic administration of the insulin-sensitising drugs, thiazolidinediones (TZDs), results in low bone mineral density and ‘fatty bones’. This is thought to be due, at least in part, to aberrant differentiation of progenitor mesenchymal stem cells (MSCs) away from osteogenesis towards adipogenesis. This study directly compared the effects of rosiglitazone, pioglitazone, and netoglitazone treatment on osteogenesis and adipogenesis in MSCs derived from subcutaneous (SC) or visceral (PV) white adipose tissue.
Featured Image
Why is it important?
This study demonstrated that the extent of lipid accumulation is dependent on the nature of the Ppar ligand and that SC and PV MSCs respond differently to in vitro TZD treatment, suggesting that metabolic status can contribute to the adverse effects associated with TZD treatment.
Perspectives
This investigation uniquely showed concurrent lipid droplet formation and mineralisation in an in vitro model of mesenchymal stem cell differentiation and provided insight into the diverse molecular signals involved in the regulation of mesenchymal stem cell lineage commitment
Dr Mari van de Vyver
Stellenbosch University
Read the Original
This page is a summary of: Thiazolidinedione-induced lipid droplet formation during osteogenic differentiation, Journal of Endocrinology, September 2014, Bioscientifica,
DOI: 10.1530/joe-14-0425.
You can read the full text:
Contributors
The following have contributed to this page
